Advertisement

Anthracycline Antibiotics in Cancer Therapy

Proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16–18 September 1981

  • Franco M. Muggia
  • Charles W. Young
  • Stephen K. Carter

Part of the Developments in Oncology book series (DION, volume 10)

Table of contents

  1. Front Matter
    Pages i-xx
  2. Biological Effects

    1. Front Matter
      Pages 1-1
    2. F. S. Philips
      Pages 3-12
    3. J. Westendorf, Hildegard Marquardt, Hans Marquardt
      Pages 30-49
  3. Mechanism of Action

    1. Front Matter
      Pages 69-69
    2. N. R. Bachur
      Pages 71-73
    3. F. Arcamone, E. Arlandini, M. Menozzi, L. Valentini, E. Vannini
      Pages 74-85
    4. N. R. Bachur
      Pages 97-102
    5. A. W. Prestayko, V. H. DuVernay, B. H. Long, S. T. Crooke
      Pages 117-124
    6. H. S. Schwartz, P. M. Kanter, A. J. Marinello, H. L. Gurtoo
      Pages 125-131
    7. C. Peterson, C. Paul, G. Gahrton, S. Vitols, M. Rudling
      Pages 132-146
    8. M. E. Scheulen, H. Muliawan, H. Kappus
      Pages 159-164
  4. Drug Development

    1. Front Matter
      Pages 173-173
    2. F. M. Muggia
      Pages 175-178
    3. F. Arcamone, A. Casazza, G. Cassinelli, A. Di Marco, S. Penco
      Pages 179-189
    4. G. Mathé, R. Maral
      Pages 190-204
    5. E. M. Acton, R. A. Jensen, J. H. Peters
      Pages 205-219
    6. C. Tihon, B. F. Issell
      Pages 247-253
    7. A. Trouet, D. Deprez-De Campeneere, R. Baurain, M. Masquelier, R. Jaenke
      Pages 274-281
    8. K. E. Rogers, E. A. Forssen, Z. A. Töklès
      Pages 282-291
  5. Cardiotoxicity

    1. Front Matter
      Pages 293-293
    2. C. E. Myers
      Pages 295-296
    3. C. Bertazzoli, U. Sammartini, M. G. Tosana, L. Ballerini, O. Bellini
      Pages 306-316
    4. J. H. Doroshow, G. Y. Locker
      Pages 317-330
    5. R. S. Benjamin, S. S. Legha, M. Valdivieṡo, M. S. Ewer, B. Mackay, S. Wallace
      Pages 352-357
    6. F. M. Torti, B. Lum, M. R. Bristow, F. E. Stockdale, M. Kohler, M. E. Billingham et al.
      Pages 358-362
    7. A. Di Marco
      Pages 363-378
  6. Doxorubicin: New Clinical Investigation

    1. Front Matter
      Pages 379-379
    2. F. M. Muggia
      Pages 381-383
    3. C. Praga, G. Beretta, O. Bawa, D. Tabanelli, P. Zanon
      Pages 384-397
    4. J. L. Speyer, M. D. Green, J. Bottino, J. Wernz, R. H. Blum, F. M. Muggia
      Pages 398-410
    5. R. F. Ozols, R. C. Young, C. E. Myers
      Pages 422-431
    6. S. S. Legha, R. S. Benjamin, B. Mackay, M. Ewer, G. Blumenschein
      Pages 432-444
    7. G. Bonadonna, C. Brambilla, A. Rossi, R. Buzzoni, A. Moliterni, P. Valagussa
      Pages 445-454
  7. Clinical Studies with New Anthracyclines and Related Compounds

    1. Front Matter
      Pages 467-467
    2. S. K. Carter
      Pages 469-470

About this book

Introduction

F. M. MUGGIA When faced with the inadequacies of current cancer treatment, we prefer to look at what the future may hold. Quite often, we take for granted the past, preferring research into totally new areas. However, the persistent development of fertile soil may yield surprising rewards for those who choose to build on the knowledge of the past--hence, this symposium on anthracycline antibiotics. Although the anthracycline antibiotics represent much of the present and future of cancer treatment, their actual use c stretches back barely two decades to the pioneering efforts of Aurelio Di Marco, who characterized the antitumor properties of daunomycin and adriamycin. * The clinical application of these two compounds heralded a decade of excitement among oncologists dealing with pediatric tumors, breast cancer, leukemias, and lymphomas, and opened new hope for patients afflicted with sar­ comas and a variety of other tumors that had been deemed - sistant to chemotherapy. These successes were tempered with the realization that the antitumor effect of anthracyclines could be achieved at times only at the very high price of risking cardiac decompensation and, almost invariably, with the occurrence of alopecia and other acute toxicities. This record of past achievements and problems has slowly given way to a present increasingly illuminated by our ability to modify the distressing toxicities of these agents. Detailed clinical studies supplemented by ingenious laboratory models have gradually elucidated mechanisms and risk factors im­ plicated in the cardiomyopathy.

Keywords

DNA antibiotics biopsy leukemia liver mutagen ovarian cancer pharmacology screening tumor

Editors and affiliations

  • Franco M. Muggia
    • 1
  • Charles W. Young
    • 2
  • Stephen K. Carter
    • 3
  1. 1.New York University Medical CenterNew YorkUSA
  2. 2.Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Northern California Oncology GroupPalo AltoUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-7630-6
  • Copyright Information Springer Science+Business Media B.V. 1982
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-009-7632-0
  • Online ISBN 978-94-009-7630-6
  • Buy this book on publisher's site